Results for tag: "Farydak"

Farydak is an oncology drug developed by Novartis, a Swiss pharmaceutical company. It is used to treat multiple myeloma, a type of cancer that affects the plasma cells in the bone marrow. Farydak is a targeted therapy, meaning it works by targeting specific proteins in the cancer cells. It is administered orally, and is usually taken in combination with other drugs. Farydak has been approved by the US Food and Drug Administration (FDA) and is available in the US and Europe. The Farydak market is highly competitive, with several other drugs available to treat multiple myeloma. These include Revlimid, Pomalyst, Kyprolis, and Imnovid. All of these drugs are targeted therapies, and are administered orally or intravenously. Companies in the Farydak market include Novartis, Celgene, Amgen, and Onyx Pharmaceuticals. These companies are all involved in the development and marketing of oncology drugs, and are actively competing in the Farydak market. Show Less Read more